Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 38, 2017, Pages 10172-10177

  Maamary, Jad ^a   Wang, Taia T ^a,b,c   Tan, Gene S ^d   Palese, Peter ^d   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHAN ZUCKERBERG BIOHUB   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CD23; Immune complex; Sialylated Fc; TIV; Universal influenza vaccine

Indexed keywords

CD23 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; IMMUNOGLOBULIN E RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HETEROLOGOUS IMMUNITY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SIALYLATION; VIRUS NEUTRALIZATION; ANIMAL; C57BL MOUSE; DOG; IMMUNOLOGY; INFLUENZA; MDCK CELL LINE; VIROLOGY;

ANIMALS; DOGS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MICE, INBRED C57BL; RECEPTORS, IGE;

EID: 85029565457     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1707950114     Document Type: Article

References (50)

1. Ekiert DC, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324:246–251.
2. Centers for Disease Control and Prevention (2016) Seasonal influenza-associated hospitalizations in the United States, https://www.cdc.gov/flu/about/qa/hospital.htm. Accessed July 16, 2017.
3. Wang TT, Parides MK, Palese P (2012) Seroevidence for H5N1 influenza infections in humans: Meta-analysis. Science 335:1463.
4. World Health Organization (2017) Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2017, www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/. Accessed July 16, 2017.
5. Halliley JL, et al. (2015) High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J Infect Dis 212:1270–1278.
6. Wang TT, et al. (2010) Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog 6:e1000796.
7. Cao RG, et al. (2014) Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. J Infect Dis 210:224–233.
8. Luo J, et al. (2012) Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein. Virol J 9:286.
9. Ledgerwood JE, et al.; VRC 306 Study Team (2011) DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect Dis 11:916–924.
10. Hai R, et al. (2012) Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes. J Virol 86:5774–5781.
11. Chen GL, et al. (2014) Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets. J Virol 88:2867–2876.
12. Chen CJ, et al. (2016) Influenza A viruses expressing intra- or intergroup chimeric hemagglutinins. J Virol 90:3789–3793.
13. Ledgerwood JE, et al.; VRC 310 Study Team (2013) Prime-boost interval matters: A randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 208:418–422.
14. Goff PH, et al. (2015) Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol 89:3221–3235.
15. Goff PH, et al. (2013) Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8:e79194.
16. Lee PS, et al. (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci USA 109: 17040–17045.
17. He W, et al. (2016) Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci USA 113:11931–11936.
18. Wrammert J, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667–671.
19. Mullarkey CE, et al. (2016) Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner. MBio 7:e01624-16.
20. DiLillo DJ, Palese P, Wilson PC, Ravetch JV (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest 126: 605–610.
21. DiLillo DJ, Tan GS, Palese P, Ravetch JV (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 20:143–151.
22. Wang TT, et al. (2015) Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell 162:160–169.
23. Pincetic A, et al. (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15:707–716.
24. Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13:277–285.
25. Fiebiger BM, Maamary J, Pincetic A, Ravetch JV (2015) Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci USA 112:E2385–E2394.
26. Dinca L, Neuwirth S, Schulman J, Bona C (1993) Induction of antihemagglutinin antibodies by polyclonal antiidiotype antibodies. Viral Immunol 6:75–84.
27. Ekiert DC, et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489:526–532.
28. Li GM, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109: 9047–9052.
29. Corti D, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850–856.
30. Armitage RJ, Goff LK (1988) Functional interaction between B cell subpopulations defined by CD23 expression. Eur J Immunol 18:1753–1760.
31. Verma N, et al. (2012) Influenza virus H1N1pdm09 infections in the young and old: Evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children. J Virol 86:5515–5522.
32. Kalergis AM, Ravetch JV (2002) Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 195: 1653–1659.
33. Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV (2017) Signaling by antibodies: Recent progress. Annu Rev Immunol 35:285–311.
34. Leon PE, et al. (2016) Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proc Natl Acad Sci USA 113:E5944–E5951.
35. Ryder AB, et al. (2015) Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains. J Virol 90:2544–2550.
36. Krammer F, Pica N, Hai R, Margine I, Palese P (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87: 6542–6550.
37. Pushko P, et al. (2017) Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens. Virology 501:176–182.
38. Pushko P, et al. (2011) Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 29:5911–5918.
39. Kanekiyo M, et al. (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499:102–106.
40. Krammer F (2017) Strategies to induce broadly protective antibody responses to viral glycoproteins. Expert Rev Vaccines 16:503–513.
41. Baz M, et al. (2015) Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge. MBio 6:e01487–e15.
42. Impagliazzo A, et al. (2015) A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349:1301–1306.
43. Memoli MJ, et al. (2016) Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. MBio 7:e00417–e16.
44. Schulman JL, Khakpour M, Kilbourne ED (1968) Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2:778–786.
45. Romero-Steiner S, et al. (1999) Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 29:281–288.
46. Usinger WR, Lucas AH (1999) Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 67: 2366–2370.
47. Sun Y, Hwang Yi, Nahm MH (2001) Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B. Infect Immun 69:336–344.
48. Bournazos S, et al. (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243–1253.
49. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475:110–113.
50. Steel J, et al. (2009) Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 83: 1742–1753.